Test Program: US-Made Drugs Get Preference in Health Programs
This act proposes a test program to see if giving preferential treatment to drugs manufactured in the United States within the Medicare, Medicaid, and CHIP programs can be beneficial. The goal is to potentially increase the availability and lower the cost of certain drugs for people in these programs by promoting domestic production.
Key points
The test program will run for at least 7 years and include at least 8 states.
US-manufactured drugs may receive preferences, such as lower patient costs or better placement on covered drug lists.
Preferences apply to generic, biosimilar, and critical drugs important, for example, in emergencies.
Expired
Citizen Poll